澳大利亚维多利亚州2021-2023年新冠疫苗接种后死亡报告详细回顾
该横断面研究描述了维多利亚州疫苗安全服务(SAEFVIC)对2021年2月22日至2023年2月22日新冠疫苗接种后死亡报告的审查流程,总结报告特征并识别死亡报告趋势。接种后前三个月报告比例为每10万剂3.98例,后续21个月为每10万剂0.71例(RR=5.61,p<0.001)。159份死亡报告中,135份(84.9%)为60岁及以上人群,143份(89.9%)被归类为「可能有其他死因」,5例死亡被国家监管机构评估为可能疫苗相关。
要点
- 接种后前3个月死亡报告比例为每10万剂3.98例,后续21个月为每10万剂0.71例(RR=5.61,p<0.001)。
- 159份死亡报告中135份(84.9%)为60岁及以上人群,121份(90.3%)存在与死因相关的合并症。
- 143份(89.9%)死亡报告经治疗临床医生/法医评估归类为「可能有其他死因」,5例(每10万剂0.03例)被国家监管机构评估为可能疫苗相关。
核心结论
- 死亡报告主要反映接种人群健康状况、疫苗接种模式及新冠疫苗相关背景因素,以及极罕见但致命的可能疫苗相关不良事件。
- SAEFVIC等辖区疫苗安全服务在死亡报告随访中发挥重要作用,支持国家监管机构工作,从而支持疫苗安全监测和疫苗信心。
研究设计与样本
- 横断面研究,纳入2021年2月22日至2023年2月22日向SAEFVIC报告的新冠疫苗接种后死亡病例。
- 描述报告特征、人口学信息和死因信息,计算每10万剂疫苗接种的死亡报告比例并按年龄(<60岁、≥60岁)、性别、疫苗类型和剂次分层,使用率比(RR)比较比例。
主要发现
- 疫苗计划前三个月报告比例为每10万剂3.98例,后续21个月为每10万剂0.71例,RR=5.61,p<0.001。
- 159份死亡报告中,135份(84.9%)为60岁及以上人群。
- 121份(90.3%)存在与死因相关的合并症。
- 143份(89.9%)经治疗临床医生/法医评估归类为「可能有其他死因」。
- 11份(6.9%)无法确定疫苗对死亡的贡献;5例死亡(每10万剂0.03例)被国家监管机构评估为可能疫苗相关,均已公开报告。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The scale of the COVID-19 vaccine program, and appropriate focus on older individuals, emphasised monitoring of mortality as an important part of COVID-19 vaccine safety surveillance, noting many deaths temporally associated with vaccination may not be causally related. This cross-sectional study describes Victoria's vaccine safety service (SAEFVIC) process of reviewing mortality reports following COVID-19 vaccination, summarises report characteristics and identifies trends in mortality reporting. METHODS: Mortality cases reported to SAEFVIC following COVID-19 vaccination from 22 February 2021 to 22 February 2023 were included. Report characteristics, demographics, and cause of death information were described. Proportions of mortality reports per 100,000 vaccine doses administered were calculated, overall and stratified by age (<60 years, ≥60 years), sex, vaccine type and dose number. Rate ratios (RR) were used to compare proportions. RESULTS: Reporting proportions were higher in the first three months of the vaccine program (3.98 per 100,000 doses), compared to the following 21 months (0.71 per 100,000 doses), RR:5.61, p < 0.001. Of 159 mortality reports included, 135/159 (84.9 %) were in individuals ≥60 years. Most individuals (121/159, 90.3 %) had comorbidities relevant to cause(s) of death, and 143/159 (89.9 %) were categorised as having a 'likely alternate' cause of death based on treating clinician/forensic assessment. For 11/159 (6.9 %) reports vaccine contribution to death could not be determined. Five deaths (0.03 per 100,000 doses administered), all publicly reported, were assessed by the national regulator as likely vaccine-associated. CONCLUSIONS: Mortality reporting predominantly reflected the health status of the population receiving vaccines, vaccine administration patterns and contextual factors surrounding COVID-19 vaccines (including public concerns regarding serious adverse events of special interest), as well as extremely rare but fatal adverse events that were likely vaccine-associated. Jurisdictional vaccine safety services such as SAEFVIC play an important role in follow-up of mortality reports, supporting the work of national regulators, and thereby supporting vaccine safety surveillance and vaccine confidence more broadly.
引用
- Laemmle-Ruff I, Fryk JJ, Shenton P, et al. Detailed review of mortality reported following COVID-19 vaccination in Victoria, Australia: 2021-2023. Vaccine. 2024. PMID: 39305837. doi:10.1016/j.vaccine.2024.126368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。